Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AVP-786 for agitation in Alzheimer's disease dementia
2017-001339-38Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and agitation comparing AVP-786 with Placebo (2 arms). Primary endpoint: Change from Baseline to Week 12 in the composite Cohen-Mansfield. Started Nov 2017; status: completed.
02
Drugs
deudextromethorphan
03
Conditions
Alzheimer's disease (AD)agitation
Beyond the preview
Go deeper on 2017-001339-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001339-38.